A study aimed to assess the relative efficacy and safety of biologics and Tofacitinib ( Xeljanz ) in patients with rheumatoid arthritis showing an inadequate response to tumor necrosis factor ( TNF ) inhibitors.
Researchers performed a Bayesian network meta-analysis to combine the direct and indirect evidence from randomized controlled trials ( RCTs ) examining the efficacy and safety of Tocilizumab ( RoActemra ), Rituximab ( MabThera ), Abatacept ( Orencia ) and Tofacitinib in patients with rheumatoid arthritis that inadequately responds to TNF inhibitors.
Four RCTs including 1796 patients met the inclusion criteria. The Tocilizumab 8 mg group showed a significantly higher American College of Rheumatology 20% ( ACR20 ) response rate than the Abatacept and Tofacitinib groups.
Ranking probability based on surface under the cumulative ranking curve ( SUCRA ) indicated that Tocilizumab 8 mg had the highest probability of being the best treatment for achieving the ACR20 response rate ( SUCRA = 0.9863 ), followed by Rituximab ( SUCRA = 0.6623 ), Abatacept ( SUCRA = 0.5428 ), Tocilizumab 4 mg ( SUCRA = 0.4956 ), Tofacitinib 10 mg ( SUCRA = 0.4715 ), Tofacitinib 5 mg ( SUCRA = 0.3415 ) and placebo ( SUCRA = 0 ).
In contrast, the safety based on the number of withdrawals due to adverse events did not differ significantly among the treatment options.
In conclusion, Tocilizumab 8 mg was the second-line non-TNF biologic with the highest performance regarding an early good response based on ACR20 response rate and acceptable safety profile, followed by Rituximab, Abatacept and Tofacitinib in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy, and none of these treatments were associated with a significant risk of withdrawal due to adverse events. ( Xagena )
Lee YH, Bae SC, Int J Rheum Dis 2015; Epub ahead of print